Patents by Inventor Paul Mays

Paul Mays has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240167023
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof. Genome engineering can refer to altering the genome by deleting, inserting, mutating, or substituting specific nucleic acid sequences. The altering can be gene or location specific. Genome engineering can use nucleases to cut a nucleic acid thereby generating a site for the alteration. Engineering of non-genomic nucleic acid is also contemplated.
    Type: Application
    Filed: May 19, 2023
    Publication date: May 23, 2024
    Applicant: Caribou Biosciences, Inc.
    Inventors: James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue, Jennifer A. Doudna, Rachel E. Haurwitz, Andrew Paul May
  • Patent number: 11505808
    Abstract: The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 22, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 11459588
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: October 4, 2022
    Assignee: CARIBOU BIOSCIENCES, INC.
    Inventors: Andrew Paul May, Paul Daniel Donohoue
  • Patent number: 11312953
    Abstract: This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 26, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 11236364
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: February 1, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Paul Daniel Donohue
  • Patent number: 11225649
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 18, 2022
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20210395709
    Abstract: The disclosure provides Cas9 protein variants that are thermostable at elevated temperatures (e.g., at least 70° C. or above). A Cas9 protein may have at least 75% sequence identity to a wild-type Cas9 protein (e.g., a wild-type Cas9 protein having the sequence of SEQ ID NO:1) and/or one or more amino acid substitutions relative to the wild-type Cas9 protein.
    Type: Application
    Filed: October 17, 2019
    Publication date: December 23, 2021
    Inventors: Stephen R. Quake, Stephanie Tzouanas Schmidt, Feiqiao Brian Yu, Paul Blainey, Andrew Paul May
  • Patent number: 11111506
    Abstract: The present specification discloses engineered Type II CRISPR-Cas9 systems comprising split-nexus Cas9-associated polynucleotides (sn-casPNs), including systems comprising three split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN/sn3-casPN) and systems comprising two split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN). Together with a Cas9 protein, the sn-casPNs facilitate site-specific modifications, including cleavage and mutagenesis, of a target polynucleotide in vitro and in vivo. Furthermore, the engineered Type II CRISPR-Cas9 systems comprising sn-casPNs are useful in methods of regulating expression of a target nucleic acid. Methods are described herein for the creation of a variety of engineered Type II CRISPR-Cas9 systems comprising two or more sn-casPNs. Polynucleotide sequences, expression cassettes, vectors, compositions, and kits for carrying out a variety of methods are also described.
    Type: Grant
    Filed: April 28, 2018
    Date of Patent: September 7, 2021
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20210252376
    Abstract: A board game incorporating the Ulam Spiral in which players compete to advance along a square spiral path of natural numbers via the prime numbers which are color coded according to the order of the subsequence of primes to which they belong. A player can occupy only one position on the board at any one time, and the player's position is determined by the prime index total that is accumulated via the roll of a die at each turn. The first player to reach the first prime number above some predetermined point on the natural number line wins the game.
    Type: Application
    Filed: April 24, 2021
    Publication date: August 19, 2021
    Inventor: Michael Paul May
  • Patent number: 11001843
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 11, 2021
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10988781
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: April 27, 2021
    Assignee: Caribou Biosciences, Inc.
    Inventors: Andrew Paul May, Paul Daniel Donohoue
  • Publication number: 20200354750
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 12, 2020
    Inventors: Andrew Paul May, Paul Daniel Donohoue
  • Patent number: 10816027
    Abstract: Intermittent screw thread geometry with a rapid step-wise lead feature when external threads are engaged with internal threads of reflective geometry. In an embodiment, thread segments are alternated with unthreaded segments of equal arc length along a helical path of a single-start thread form which results in an odd number of alternating thread/gap features along the helical path per revolution of the thread body. When such external intermittent threads engage internal intermittent threads of reflective geometry, an external thread body can be axially advanced or retracted through an internal thread body in a rapid step-wise fashion by turning the external thread body in either the clockwise or counterclockwise direction, or in both directions alternately, with respect to the internal thread body when a net axial force is applied to the external threaded body with respect to the internal thread body in the desired linear direction of travel.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 27, 2020
    Inventor: Michael Paul May
  • Publication number: 20200318088
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10711258
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 14, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20200208155
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10590415
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 17, 2020
    Assignee: Ceribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20200071684
    Abstract: The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Publication number: 20200056209
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Application
    Filed: October 31, 2019
    Publication date: February 20, 2020
    Inventors: Andrew Paul May, Paul Daniel Donohoue
  • Patent number: 10519468
    Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 31, 2019
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Andrew Paul May, Paul Daniel Donohoue